Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Human Research Protection Alternative Models Discussed By OHRP’s Koski

This article was originally published in The Gray Sheet

Executive Summary

A human subjects protection strategy in which a central review panel works with a set of local review boards to improve safety for research participants is among several alternative models worth exploring, HHS Office of Human Research Protections Director Greg Koski, MD/PhD, told an Institute of Medicine Clinical Research Roundtable workshop Nov. 5

You may also be interested in...



Regional Boards Would Replace IRBs Under NIH Bioethics Proposal

A proposal to dramatically restructure the nation's current human research subjects protection system by extending federal regulations to all human research and replacing local institutional review boards with regional ethics boards (REBs) is being circulated at NIH by the Department of Clinical Bioethics

QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

UsernamePublicRestriction

Register

MT017450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel